THALES
8.12.2021 08:02:06 CET | Business Wire | Press release
Gireve, the leading B2B digital platform for electric mobility, and Thales, leader in digital security, have collaborated to provide a simple and secure ´Plug & Charge´ access and billing system. The joint solution, based on the Thales Trusted Key Manager and Gireve’s intermediation platform, improves the driver experience, builds trust in a multi players’ ecosystem and also helps meet the ISO 15118 International standard.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006154/en/
While the EV market rapidly expands, convenient access to charging networks becomes a priority. The current charging network is still very fragmented, often proprietary and not available in enough places. A global standardized and interoperable solution is needed as well as an improved management of the delivery of electricity.
Today each e-Mobility Service Provider (eMSP) offers EV drivers an RFID card to access and start a charging session. Gireve and Thales have partnered to create a harmonized ´Plug & Charge´ solution to simplify the experience and ensure the highest level of security for all EV market players.
Drivers simply plug their electric car into any ISO 15118-compatible charging station, without using a physical card, and the billing is automatically associated to the subscription managed for them. As a result drivers can then freely choose an e-Mobility Service Provider and access a wider number of charging stations; while benefitting from a secure automated charging and digital payment experience.
The solution delivers unique credential certificates to each actor in the system from driver to vehicle and charging station. The system, based on Thales Trusted Key Manager then ensures the secure and instant mutual authentication between these actors. The solution also verifies that the right credentials are securely generated and distributed from the right e-Mobility Provider to the associated vehicle and user. The result – a simpler and more secure EV charging experience.
This mutual authentication and secure credentials management also set the basis of a trusted environment for coming smart grid deployments. As the EV market is expected to boom in the coming years, so does electricity need. Indeed, such increasing needs will require improved and safe energy management and delivery to address power peaks demand.
“ For almost 10 years, Gireve has been a central trusted third party for B2B players in the charging sector. Together with Thales, we are confident our solution addresses key challenges to back up the sustainable success of the EV ecosystem. Our joint efforts are all about facilitating energy access, bringing trust through cybersecurity and boosting drivers’ adoption with improved usage.” Eric Plaquet, CEO at Gireve
“Gireve offered Thales a great opportunity to deploy its field-proven expertise in strong authentication and cybersecurity to the smart charging market. Our partnership supports the sustainable e-mobility sector, by smoothing EV charging access and by creating the trust the sector needs to succeed. Looking forward, our collaboration may unleash further use cases to support smart grid development with more efficient energy management.” Christine Caviglioli, Vice President Automotive at Thales
1
https://www.delta-ee.com/downloads/1-research-downloads/2830-whitepaper-ev-forecasts-84-million-evs-on-european-roads-by-2030.html
2
ISO 15118 is an international standard that outlines the digital communication protocol that an electric vehicle (EV) and charging station should use to recharge the EV’s high-voltage battery.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About GIREVE
Combining Market Place, Transactions Processing, and Data Management technologies, GIREVE is the leading B-to-B digital platform for electric recharging, offering the first coverage in terms of number of charge points in Europe. The company manages 3,800 contracts between 277 players in 32 countries and references more than 220,000 charge points, including 149,000 open to roaming.
For almost 10 years, GIREVE has been a central trusted third party for B-to-B players in the charging sector, handling negotiations and transactions independently, securely, according to transparent rules, and in compliance with regulations.
PLEASE VISIT
Thales Group
Market page
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
